Skip to main content
. 2021 Dec 18;16(5):1072–1090. doi: 10.1002/1878-0261.13151

Fig. 5.

Fig. 5

SRC and MEK inhibitor combinations do not sensitise drug‐induced resistant cells. (A) Cell viability of cells treated with trametinib. TRAMR. Isogenic wild‐type KRAS HCT116 cells (HKH2). Data are means ± SEM (n = 3 independent experiments). EC50 values are shown in parentheses. (B) Cell viability of HKH2 and TRAMR cells in combination with AZD0424 after 3‐day treatment. Mean cell viability is shown ± SEM (n = 3 independent experiments). (C) Western blot analysis of lysates from cells treated with AZD0424 (2000 nm) or trametinib (5 nm) for 24 h. Representative blots are shown from n = 3 independent experiments. (D) RPPA analysis of lysates from cells treated with AZD0424 (2000 nm), AZD6244 (2000 nm) and trametinib (5 nm) for 24 h. Hierarchal clustering using Euclidean distance and complete linkage is shown. Values are normalised to DMSO‐treated samples. Data are from n = 2 (for HCT116 cells) and n = 3 (TRAMR) independent experiments.